SCHEMBL5281759

SCHEMBL5281759

CC(C)(CN)CCC(N)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BHMT Q93088 3/20 0.49
GSR P00390 2/20 0.47
KIF11 P52732 6/20 0.46
CPB1 P15086 1/20 0.45
CPB2 Q96IY4 1/20 0.45
GRM8 O00222 1/20 0.45
GRM6 O15303 1/20 0.45
GRIN2D O15399 1/20 0.45
GRIN3B O60391 1/20 0.45
CYP1A2 P05177 1/20 0.45
GRIK1 P39086 1/20 0.45
GRM5 P41594 1/20 0.45
GRIA1 P42261 1/20 0.45
GRIA2 P42262 1/20 0.45
GRIA3 P42263 1/20 0.45
SLC1A3 P43003 1/20 0.45
SLC1A2 P43004 1/20 0.45
SLC1A1 P43005 1/20 0.45
GRIA4 P48058 1/20 0.45
GRIN1 Q05586 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18894223 1.00 BHMT (0.49) BHMTGSRKIF11CPB1CPB2
SCHEMBL19734386 0.90 BHMT (0.45) BHMTGSRKIF11CPB1CPB2
SCHEMBL4838885 0.83 BHMT (0.49) BHMTGSRKIF11GRM8GRM6
SCHEMBL4837844 0.83 BHMT (0.49) BHMTGSRKIF11GRM8GRM6
SCHEMBL14420362 0.80 KIF11 (0.50) BHMTGSRKIF11GRM8GRM6
SCHEMBL5697661 0.80 KIF11 (0.50) BHMTGSRKIF11GRM8GRM6
SCHEMBL8418914 0.80 KIF11 (0.50) BHMTGSRKIF11GRM8GRM6
SCHEMBL19232136 0.78 KIF11 (0.48) BHMTGSRKIF11GRM8GRM6
Hydrochloric Acid SCHEMBL319257 0.78 NOS2 (0.50) BHMTGSRKIF11GRM8GRM6
Hydrochloric Acid SCHEMBL29213474 0.78 NOS2 (0.50) BHMTGSRKIF11GRM8GRM6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220226496-A1 LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE LEGOCHEM BIOSCIENCES, INC. (KR) 2022-07-21 US claimed
EP-3964236-A1 LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE LegoChem Biosciences, Inc. (KR) 2022-03-09 EP claimed
US-11167040-B2 Conjugates comprising peptide groups and methods related thereto LEGOCHEM BIOSCIENCES, INC. (KR) 2021-11-09 US claimed
EP-3380125-A1 CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO LegoChem Biosciences, Inc. (KR) 2018-10-03 EP claimed
CN-108136038-A Conjugates comprising peptide groups and methods related thereto 乐高化学生物科学股份有限公司 2018-06-08 CN claimed
WO-2017089894-A1 CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO LEGOCHEM BIOSCIENCES, INC. (KR) 2017-06-01 WO claimed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 US claimed
US-20260124278-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS D&D PHARMATECH INC (KR) 2026-05-07 US disclosed
US-20250296960-A1 PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF D&D PHARMATECH INC. (KR) 2025-09-25 US disclosed
US-20250127723-A1 PHARMACEUTICAL COMPOSITION COMPRISING LARGE PHYSIOLOGICALLY ACTIVE SUBSTANCE AND EXCIPIENT D&D PHARMATECH INC. (KR) 2025-04-24 US disclosed
EP-4532530-A1 PEPTIDE COMPOSITIONS AND METHODS OF USE THREOF D&D Pharmatech Inc. (KR) 2025-04-09 EP disclosed
EP-4531925-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS D&D Pharmatech Inc. (KR) 2025-04-09 EP disclosed
EP-4400094-A1 PHARMACEUTICAL COMPOSITION COMPRISING LARGE PHYSIOLOGICALLY ACTIVE SUBSTANCE AND EXCIPIENT D&D Pharmatech Inc. (KR) 2024-07-17 EP disclosed
US-6699855-B2 PYRROLOPYRAZINONES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2004-03-02 US disclosed
US-20020177725-A1 Peptide inhibitors of hepatitis C virus NS3 protein BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) 2002-11-28 US disclosed
US-20020123468-A1 Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-09-05 US disclosed
US-20020065248-A1 Inhibitors of hepatitis C virus NS3 protease BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-05-30 US disclosed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 US disclosed
EP-0787010-A1 AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-06 EP disclosed
WO-1996012499-A1 AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11167040-B2 Conjugates comprising peptide groups and methods related thereto DAO, LPO, TYRO3 BHMT 544/4885GSR 2760/4885KIF11 3435/4885
US-20250127723-A1 PHARMACEUTICAL COMPOSITION COMPRISING LARGE PHYSIOLOGICALLY ACTIVE SUBSTANCE AND EXCIPIENT CYP7A1, CYP11B1, CYP11B2 BHMT 3240/4885GSR 228/4885KIF11 1674/4885
US-20020065248-A1 Inhibitors of hepatitis C virus NS3 protease TMPRSS15, CTRC, CPN1 BHMT 2833/4885GSR 2564/4885KIF11 4542/4885
US-20220226496-A1 LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE TNFSF10, TNFRSF9, ANTXR2 BHMT 4594/4885GSR 4145/4885KIF11 806/4885
US-20020177725-A1 Peptide inhibitors of hepatitis C virus NS3 protein VIP, PRSS1, SERPINB1 BHMT 3408/4885GSR 3815/4885KIF11 4131/4885
US-20250296960-A1 PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF GLP1R, IAPP, GIPR BHMT 1006/4885GSR 744/4885KIF11 4339/4885
US-20260124278-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS GLP1R, IAPP, VIP BHMT 202/4885GSR 256/4885KIF11 3619/4885
US-20020123468-A1 Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease CES1, CYP51A1, SPINT2 BHMT 2227/4885GSR 3752/4885KIF11 841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.